Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold.

A research team led by Associate Professor Makoto Ikeya in the Department of Clinical Application at Kyoto University has ...

Princeton University awarded honorary degrees to Omar M. Yaghi, Daniel Chee Tsui, Nancy Weiss Malkiel, Joshua ...

The next-gen immunotherapies market is evolving with biotech advances, rising cancer cases, new therapies, funding, and ...

Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and ...

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

Fourth, talent will be the X-factor—biomanufacturing’s future turns on a specialised workforce trained at the intersection of ...

The regenerative medicine market is an exciting and rapidly evolving sector within the healthcare industry. This market focuses on the development and application of therapies and technologies ...

One of the key advantages of CAR T-cell therapy is that it does not cause the side-effects associated with chemotherapy and ...

Explore how CRISPR could become a powerful antiviral tool against HIV, Hepatitis B, HPV, and more, based on emerging research.

In a stunning medical breakthrough that effectively brings designer babies out of the realm of science fiction, a ...